[
  {
    "sentence": "The p.V617F mutation disrupts this inhibitory role of JH2, leading to constitutive activation of JH1 and the downstream JAK-STAT signaling cascade.2 Additional clinically significant variants in exon 12 of JAK2 as well as less common variants across exons 12 to 15 within the pseudokinase domain and throughout the entire gene have been identified for patients with MPN.3,4\nAlthough most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MPN associated with germ line JAK2 variants can occur either in the absence of additional variants in JAK2, CALR, or MPL (idiopathic or “triple-negative”)13 or alongside acquired variants, including p.V617F-positive MPN.21 Additionally, the JAK2 46/1 haplotype, consisting of 4 single nucleotide polymorphisms within intronic regions of JAK2, is present in up to 45% of the general population and has been observed to confer a somewhat increased risk of acquiring p.V617F, leading to MPN development (odds ratio, 3.07; 95% confidence interval, 1.73–5.46).22,23\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "FERM, four-point-one ezrin, radixin, moesin domain; SH2, Src homology domain 2.Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The p.V617F mutation disrupts this inhibitory role of JH2, leading to constitutive activation of JH1 and the downstream JAK-STAT signaling cascade.2 Additional clinically significant variants in exon 12 of JAK2 as well as less common variants across exons 12 to 15 within the pseudokinase domain and throughout the entire gene have been identified for patients with MPN.3,4\nAlthough most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MPN associated with germ line JAK2 variants can occur either in the absence of additional variants in JAK2, CALR, or MPL (idiopathic or “triple-negative”)13 or alongside acquired variants, including p.V617F-positive MPN.21 Additionally, the JAK2 46/1 haplotype, consisting of 4 single nucleotide polymorphisms within intronic regions of JAK2, is present in up to 45% of the general population and has been observed to confer a somewhat increased risk of acquiring p.V617F, leading to MPN development (odds ratio, 3.07; 95% confidence interval, 1.73–5.46).22,23\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "FERM, four-point-one ezrin, radixin, moesin domain; SH2, Src homology domain 2.Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The p.V617F mutation disrupts this inhibitory role of JH2, leading to constitutive activation of JH1 and the downstream JAK-STAT signaling cascade.2 Additional clinically significant variants in exon 12 of JAK2 as well as less common variants across exons 12 to 15 within the pseudokinase domain and throughout the entire gene have been identified for patients with MPN.3,4\nAlthough most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MPN associated with germ line JAK2 variants can occur either in the absence of additional variants in JAK2, CALR, or MPL (idiopathic or “triple-negative”)13 or alongside acquired variants, including p.V617F-positive MPN.21 Additionally, the JAK2 46/1 haplotype, consisting of 4 single nucleotide polymorphisms within intronic regions of JAK2, is present in up to 45% of the general population and has been observed to confer a somewhat increased risk of acquiring p.V617F, leading to MPN development (odds ratio, 3.07; 95% confidence interval, 1.73–5.46).22,23\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "FERM, four-point-one ezrin, radixin, moesin domain; SH2, Src homology domain 2.Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The p.V617F mutation disrupts this inhibitory role of JH2, leading to constitutive activation of JH1 and the downstream JAK-STAT signaling cascade.2 Additional clinically significant variants in exon 12 of JAK2 as well as less common variants across exons 12 to 15 within the pseudokinase domain and throughout the entire gene have been identified for patients with MPN.3,4\nAlthough most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MPN associated with germ line JAK2 variants can occur either in the absence of additional variants in JAK2, CALR, or MPL (idiopathic or “triple-negative”)13 or alongside acquired variants, including p.V617F-positive MPN.21 Additionally, the JAK2 46/1 haplotype, consisting of 4 single nucleotide polymorphisms within intronic regions of JAK2, is present in up to 45% of the general population and has been observed to confer a somewhat increased risk of acquiring p.V617F, leading to MPN development (odds ratio, 3.07; 95% confidence interval, 1.73–5.46).22,23\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "FERM, four-point-one ezrin, radixin, moesin domain; SH2, Src homology domain 2.Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The p.V617F mutation disrupts this inhibitory role of JH2, leading to constitutive activation of JH1 and the downstream JAK-STAT signaling cascade.2 Additional clinically significant variants in exon 12 of JAK2 as well as less common variants across exons 12 to 15 within the pseudokinase domain and throughout the entire gene have been identified for patients with MPN.3,4\nAlthough most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MPN associated with germ line JAK2 variants can occur either in the absence of additional variants in JAK2, CALR, or MPL (idiopathic or “triple-negative”)13 or alongside acquired variants, including p.V617F-positive MPN.21 Additionally, the JAK2 46/1 haplotype, consisting of 4 single nucleotide polymorphisms within intronic regions of JAK2, is present in up to 45% of the general population and has been observed to confer a somewhat increased risk of acquiring p.V617F, leading to MPN development (odds ratio, 3.07; 95% confidence interval, 1.73–5.46).22,23\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "FERM, four-point-one ezrin, radixin, moesin domain; SH2, Src homology domain 2.Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The p.V617F mutation disrupts this inhibitory role of JH2, leading to constitutive activation of JH1 and the downstream JAK-STAT signaling cascade.2 Additional clinically significant variants in exon 12 of JAK2 as well as less common variants across exons 12 to 15 within the pseudokinase domain and throughout the entire gene have been identified for patients with MPN.3,4\nAlthough most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MPN associated with germ line JAK2 variants can occur either in the absence of additional variants in JAK2, CALR, or MPL (idiopathic or “triple-negative”)13 or alongside acquired variants, including p.V617F-positive MPN.21 Additionally, the JAK2 46/1 haplotype, consisting of 4 single nucleotide polymorphisms within intronic regions of JAK2, is present in up to 45% of the general population and has been observed to confer a somewhat increased risk of acquiring p.V617F, leading to MPN development (odds ratio, 3.07; 95% confidence interval, 1.73–5.46).22,23\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "FERM, four-point-one ezrin, radixin, moesin domain; SH2, Src homology domain 2.Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The p.V617F mutation disrupts this inhibitory role of JH2, leading to constitutive activation of JH1 and the downstream JAK-STAT signaling cascade.2 Additional clinically significant variants in exon 12 of JAK2 as well as less common variants across exons 12 to 15 within the pseudokinase domain and throughout the entire gene have been identified for patients with MPN.3,4\nAlthough most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MPN associated with germ line JAK2 variants can occur either in the absence of additional variants in JAK2, CALR, or MPL (idiopathic or “triple-negative”)13 or alongside acquired variants, including p.V617F-positive MPN.21 Additionally, the JAK2 46/1 haplotype, consisting of 4 single nucleotide polymorphisms within intronic regions of JAK2, is present in up to 45% of the general population and has been observed to confer a somewhat increased risk of acquiring p.V617F, leading to MPN development (odds ratio, 3.07; 95% confidence interval, 1.73–5.46).22,23\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "FERM, four-point-one ezrin, radixin, moesin domain; SH2, Src homology domain 2.Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The p.V617F mutation disrupts this inhibitory role of JH2, leading to constitutive activation of JH1 and the downstream JAK-STAT signaling cascade.2 Additional clinically significant variants in exon 12 of JAK2 as well as less common variants across exons 12 to 15 within the pseudokinase domain and throughout the entire gene have been identified for patients with MPN.3,4\nAlthough most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MPN associated with germ line JAK2 variants can occur either in the absence of additional variants in JAK2, CALR, or MPL (idiopathic or “triple-negative”)13 or alongside acquired variants, including p.V617F-positive MPN.21 Additionally, the JAK2 46/1 haplotype, consisting of 4 single nucleotide polymorphisms within intronic regions of JAK2, is present in up to 45% of the general population and has been observed to confer a somewhat increased risk of acquiring p.V617F, leading to MPN development (odds ratio, 3.07; 95% confidence interval, 1.73–5.46).22,23\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "FERM, four-point-one ezrin, radixin, moesin domain; SH2, Src homology domain 2.Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The p.V617F mutation disrupts this inhibitory role of JH2, leading to constitutive activation of JH1 and the downstream JAK-STAT signaling cascade.2 Additional clinically significant variants in exon 12 of JAK2 as well as less common variants across exons 12 to 15 within the pseudokinase domain and throughout the entire gene have been identified for patients with MPN.3,4\nAlthough most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MPN associated with germ line JAK2 variants can occur either in the absence of additional variants in JAK2, CALR, or MPL (idiopathic or “triple-negative”)13 or alongside acquired variants, including p.V617F-positive MPN.21 Additionally, the JAK2 46/1 haplotype, consisting of 4 single nucleotide polymorphisms within intronic regions of JAK2, is present in up to 45% of the general population and has been observed to confer a somewhat increased risk of acquiring p.V617F, leading to MPN development (odds ratio, 3.07; 95% confidence interval, 1.73–5.46).22,23\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "FERM, four-point-one ezrin, radixin, moesin domain; SH2, Src homology domain 2.Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Although most JAK2 variants, including p.V617F, occur as acquired, somatic mutations, germ line JAK2 variants have been reported in association with hereditary thrombocythemia (HT), hereditary erythrocytosis (HE), and familial predisposition to MPN.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 These germ line variants are reported throughout the pseudokinase and kinase domains, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Etheridge et al previously reported a family in which JAK2 p.R564Q segregated with familial ET and demonstrated through functional studies that p.R564Q causes increased activation of the JAK2 protein in platelets and suppression of apoptosis, leading to increased cell growth.17 Here, we describe a family including patients from 3 generations with p.R564Q associated with either congenital idiopathic thrombocythemia or lymphocytosis (Figure 2), as well as 2 patients with idiopathic thrombocythemia and confirmed germ line variants in an alternative variant at the same residue, p.R564L.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Her family history included a 27-year-old son with reported thrombocytosis (∼500 × 103/μL) (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Structural analysis revealed that the p.R564L mutation disrupts the local structure of the protein, particularly affecting the interaction network involving the residues H538, E566, and Y613, as depicted in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "It was proposed that p.R564Q can interfere with JH2 inhibition by SH2, leading to increased transphosphorylation of JH1 by disrupting hydrogen bonding hypothesized between p.R564 and p.H538 within JH2, based on the crystal structure of the pseudokinase domain34 (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]